BostonGene, a leader in AI-driven cancer and immune system research, announced it will present four scientific posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, scheduled for November 5–9, 2025, in National Harbor, Maryland. The company will also exhibit at booth 319 during the event. BostonGene will showcase its omnimodal foundation AI platform, highlighting breakthrough applications in precision oncology. The research demonstrates the model’s ability to identify predictive biomarkers, improve patient selection for clinical trials, forecast treatment-related toxicities using blood-based profiling, and evaluate the effectiveness of combination therapies—specifically in B-cell non-Hodgkin lymphoma. The presentations include: Friday, November 7 – Abstract 153: Association of candidate tertiary lymphoid structures in baseline tumor tissue with response to ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC) Saturday, November 8 – Abstract 154: Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy Abstract 504: Biological Mechanisms of Resistance to Macrophage Checkpoint Inhibitors in Relapsed B-cell Non-Hodgkin Lymphoma Abstract 1094: Pre-treatment predictive modeling of immune-related adverse event risk in immune checkpoint blockade therapy: A multi-modal machine learning approach from a real-world setting (RADIOHEAD Cohort Study) All abstracts will be published on November 4 in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s official journal. BostonGene’s foundation model is built on a vast real-world clinical testing network, integrating genomic, transcriptomic, and immune data with clinical outcomes. This enables the generation of biologically grounded, actionable insights that support biopharmaceutical partners in de-risking clinical trials, identifying novel therapeutic targets, and improving predictions of treatment response across all stages of drug development—while also advancing patient care through integrated innovation. For more information or to schedule a meeting with BostonGene at SITC, contact Hannah Oman at [email protected]. About BostonGene Corporation BostonGene is transforming cancer care and drug development by combining omnimodal data with artificial intelligence. Its foundation model of cancer and the immune system is designed to deliver clinically relevant insights that enhance trial design, accelerate target discovery, and improve therapeutic outcomes. For more information, visit www.BostonGene.com. Media Contact: Erin Keleher +1-617-283-2285 [email protected]